MEET OUT RESIDENTS
Arxx Therapeutics develops a first-in-class monoclonal antibody with a unique mechanism of action targeting non-resolving tissue fibrosis
We are leveraging more than 30 years of research by our scientific co-founders uncovering the pathobiology of S100A4 – a Damage Associated Molecular Pattern protein upregulated upon stress or injury allowing cells to sense and react to danger. In chronically diseased tissue, S100A4 is inappropriately activated which leads to persistent inflammation and fibrogenesis. Our lead candidate AX-202 is a high-affinity monoclonal antibody neutralizing the bioactivity of S100A4.